Provention bio provides update on the potential timing of teplizumab at-risk type 1 diabetes (t1d) biologics license application (bla) resubmission

Red bank, n.j., sept. 13, 2021 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on the status and timing of its ongoing efforts to address fda considerations cited in the complete response letter (crl) issued to the company by the fda on july 2, 2021.
PRVB Ratings Summary
PRVB Quant Ranking